Media stories about MannKind Corporation (NASDAQ:MNKD) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. MannKind Corporation earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 46.1917071534041 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Here are some of the news headlines that may have effected Accern Sentiment’s analysis:

MannKind Corporation (NASDAQ:MNKD) opened at 1.98 on Monday. The firm has a market capitalization of $207.27 million, a price-to-earnings ratio of 1.49 and a beta of 3.16. MannKind Corporation has a one year low of $0.67 and a one year high of $4.35. The firm has a 50-day moving average price of $1.63 and a 200-day moving average price of $1.46.

MannKind Corporation (NASDAQ:MNKD) last issued its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.10). The firm had revenue of $2.16 million during the quarter, compared to the consensus estimate of $2.75 million. MannKind Corporation had a net margin of 71.60% and a negative return on equity of 24.93%. During the same quarter in the previous year, the firm earned $0.08 earnings per share. Analysts expect that MannKind Corporation will post ($0.94) EPS for the current year.

A number of equities research analysts recently weighed in on the company. Maxim Group restated a “buy” rating on shares of MannKind Corporation in a research note on Friday, September 1st. ValuEngine lowered MannKind Corporation from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Finally, Zacks Investment Research lowered MannKind Corporation from a “hold” rating to a “sell” rating in a report on Saturday, August 12th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and one has issued a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $0.92.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect MannKind Corporation (MNKD) Stock Price” was posted by Daily Political and is the property of of Daily Political. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at

About MannKind Corporation

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.

Insider Buying and Selling by Quarter for MannKind Corporation (NASDAQ:MNKD)

Receive News & Ratings for MannKind Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind Corporation and related companies with's FREE daily email newsletter.